Anti-VEGFs are fundamental to many an oncology and ophthalmology franchise. But for wet age-related macular degeneration (AMD) patients, targeting vascular endothelial growth factor (VEGF) seems to offer only a temporary solution for a few years that may, in fact, thereafter accelerate patient vision loss by contributing to fibrosis and exacerbating the underlying pathology.
Ophthotech Underscores Limitations Of Anti-VEGFs in Wet AMD
The biotech took aim at ophthalmic rival Regeneron with a panel of physicians who pointed out the short-term nature of and side-effects associated with anti-VEGFs. It also emphasized that doctors want several treatments with distinct mechanisms of action, rather than the co-formulations that Regeneron plans.
More from Clinical Trials
More from R&D
• By
Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview.
• By
The European Medicines Agency’s chief, Emer Cooke, explained how the agency could help companies with their drug development plans, and said the EU Health Technology Assessment Regulation would help companies design clinical trials that are fit for regulators and HTA bodies.
• By
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.